Trial reportStroke2022
Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study.
Trial report in Stroke, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02546323. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects
Open the trial in the graphWho cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Pharmacological interventions for asymptomatic carotid stenosis.The Cochrane database of systematic reviews · 2023 · on this mapPooled it
- Cascade-Activatable Nanoprobes for NIR-II Fluorescence/Photoacoustic Dual-Modal Imaging of Atherosclerotic Plaques.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Lipoprotein(a) Does Not Correlate with Hypertensive Mediated Organ Damage and Subsequent Cardiovascular Events in a Primary Prevention Cohort.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Article
- Myocardial infarction, stroke and arterial stenosis: time to reassess a major misunderstanding.Nature reviews. Cardiology · 2026Review
- Detection of aspartyl aminopeptidase in atherosclerosis mice and clinical sample using an optical probe.Materials today. Bio · 2025Article
- Comparative effectiveness and safety of atorvastatin versus rosuvastatin among patients with ischemic stroke or transient ischemic attack: a national registry-based observational study.EClinicalMedicine · 2025Article
- Article
- Interaction between 24 h Urinary Free Cortisol and Obesity in Hypertension-Mediated Organ Damage in Patients with Untreated Hypertension.Reviews in cardiovascular medicine · 2025Article
- Effect of folic acid and vitamin B12 plus rosuvastatin in the treatment of coronary heart disease combined with hyperlipidemia.Frontiers in cardiovascular medicine · 2025Article
- Hashimoto's thyroiditis and thyroid hormone sensitivity in euthyroid individuals: their association with carotid plaque in northeast China.Frontiers in endocrinology · 2025Article
- The Possible Role of Rosuvastatin Therapy in HFpEF Patients-A Preliminary Report.Diagnostics (Basel, Switzerland) · 2024Article
- The Effect of Statins on Carotid Intima-Media Thickness and C-Reactive Protein in Type 2 Diabetes Mellitus: A Meta-Analysis.Journal of cardiovascular development and disease · 2024Review
- Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk.Journal of clinical medicine · 2024Review
- Ethnic Differences in Carotid Intima-Media Thickness and Plaque Presence: The HELIUS Study.Cerebrovascular diseases (Basel, Switzerland) · 2024Article
- Landscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease.Reviews in cardiovascular medicine · 2023Review
- High Uric Acid Promotes Atherosclerotic Plaque Instability by Apoptosis Targeted Autophagy.Journal of atherosclerosis and thrombosis · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 12 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtherosclerosis is the leading cause of cardiovascular disease worldwide, including in China. Primary prevention, through lipid-lowering, could avert development of atherosclerosis. Carotid intima-media thickness (CIMT) is a well-validated measure of atherosclerosis used in intervention studies as the primary outcome and alternative end point for cardiovascular disease events.
methodsThis randomized, double-blind, placebo-controlled, multicenter, parallel-group study assessed the effects of rosuvastatin 20 mg/d compared with placebo on progression of CIMT over 104 weeks in Chinese people with subclinical atherosclerosis. The primary end point was the annualized rate of change in mean of the maximum CIMT measurements taken 7× over the study period from each of 12 carotid artery sites (near and far walls of the right and left common carotid artery, carotid bulb, and internal carotid artery). Secondary end points included CIMT changes at different artery sites and lipid-parameter changes. Safety was also assessed.
resultsParticipants were randomized (1:1) to receive rosuvastatin (n=272) or placebo (n=271). Baseline characteristics were well balanced between groups. The change in mean of the maximum CIMT of the 12 carotid sites was 0.0038 mm/y (95% CI, -0.0023-0.0100) for the rosuvastatin group versus 0.0142 mm/y (95% CI, 0.0080-0.0204) for the placebo group, with a difference of -0.0103 mm/y (95% CI, -0.0191 to -0.0016;
conclusionsRosuvastatin 20 mg/d significantly reduced the progression of CIMT over 2 years in Chinese adults with subclinical atherosclerosis and was well tolerated. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02546323.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.